Illumina, Sequenom Settle Patent Lawsuit

San Diego-based Illumina and fellow San Diego company Sequenom said the two have ended a patent dispute, with Illumina paying Sequenom $50M, plus additional payments through 2020. The two also said they will pool their noninvasive, prenatal testing intellectual property, and that Illumina will gain the exclusive worldwide rights to utilize that intellectual property to develop and sell in-viitro diagnostics kits for noninvasive prenatal testing, with both companies sharing revenue from the patent pool. Illumina will also supply Sequenom with instruments and reagents.